|
|
Halozyme Therapeutics Inc (HALO) |
|
|
|
Halozyme Therapeutics Inc 's Yearly EPS from Cont. Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual EPS from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual EPS from Cont. Operations Annual Growth Rates Y/Y▼
|
HALO Annual EPS from Cont. Operations Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
Y / Y Annual EPS from Cont. Operations Change |
43.92 % |
-48.25 % |
201.05 % |
- |
- |
Annual EPS from Cont. Operations (in $) |
$2.13 |
$1.48 |
$2.86 |
$0.95 |
$-0.50 |
Annual EPS from Cont. Operations Growth
Comment |
Halozyme Therapeutics Inc 's Annual EPS from Cont. Operations for the fiscal year ended 2023, soared by 43.92% to $2.13, from $1.48 achieved a year ago. Halozyme Therapeutics Inc 's growrh rate for EPS from Cont. Operations improved from -48.25 % decline in the fiscal year 2022.
Halozyme Therapeutics Inc Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2023 Annual EPS from Cont. Operations within Healthcare Sector | Y/Y EPS from Cont. Operations Growth % | 2023 Annual EPS from Cont. Operations | Moderna Inc | | | |